Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia

Bo Kyung Kim; Kyung Taek Hong; Hyoung Jin Kang; Hong Yul An; Jung Yoon Choi; Che Ry Hong; Kyung Duk Park; Dong Soon Lee; Hee Young Shin

doi:10.1097/MPH.0000000000001237

Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia

Bo Kyung Kim, Kyung Taek Hong, Hyoung Jin Kang, Hong Yul An, Jung Yoon Choi, Che Ry Hong, Kyung Duk Park, Dong Soon Lee, Hee Young Shin

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.

Original language	English
Pages (from-to)	e336-e337
Journal	Journal of Pediatric Hematology/Oncology
Volume	41
Issue number	5
DOIs	https://doi.org/10.1097/MPH.0000000000001237
State	Published - 1 Jul 2019

Bibliographical note

Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

Epstein-Barr virus
aggressive NK cell leukemia
allogeneic hematopoietic stem cell transplantation

Access to Document

10.1097/MPH.0000000000001237

Cite this

@article{5adfb5c6d6e44897888c3428fbe6052b,

title = "Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia",

abstract = "Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.",

keywords = "Epstein-Barr virus, aggressive NK cell leukemia, allogeneic hematopoietic stem cell transplantation",

author = "Kim, {Bo Kyung} and Hong, {Kyung Taek} and Kang, {Hyoung Jin} and An, {Hong Yul} and Choi, {Jung Yoon} and Hong, {Che Ry} and Park, {Kyung Duk} and Lee, {Dong Soon} and Shin, {Hee Young}",

year = "2019",

month = jul,

day = "1",

doi = "10.1097/MPH.0000000000001237",

language = "English",

volume = "41",

pages = "e336--e337",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia

AU - Kim, Bo Kyung

AU - Hong, Kyung Taek

AU - Kang, Hyoung Jin

AU - An, Hong Yul

AU - Choi, Jung Yoon

AU - Hong, Che Ry

AU - Park, Kyung Duk

AU - Lee, Dong Soon

AU - Shin, Hee Young

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.

AB - Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.

KW - Epstein-Barr virus

KW - aggressive NK cell leukemia

KW - allogeneic hematopoietic stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85048298340&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001237

DO - 10.1097/MPH.0000000000001237

M3 - Article

C2 - 29889803

AN - SCOPUS:85048298340

SN - 1077-4114

VL - 41

SP - e336-e337

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 5

ER -

Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this